tezemlimogene daxadenorepvec
AXP000036.1 · Oncolytic virus
- Platform
- adenovirus (Ad5 Delta-24-RGD, OX40L-armed)
- Originator
- The University of Texas MD Anderson Cancer Center
- Sponsor
- DNAtrix
Names
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5 Delta-24-RGD
- Replication
- conditionally replicating
- Modifications
- Delta-24 E1A; RGD-4C fiber; OX40L transgene
- Transgenes
- TNFSF4
- Route
- intratumoral, intra arterial
- Source
- evidence
Cross-references
- NCI Thesaurus
- C160192
- FDA UNII
- B7N7BR6M4A
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04714983 | DNX-2440 for Resectable Colorectal Liver Metastasis | Suspended | Phase 1 | 2021-02-15 | 2026-07-31 | 30 | Breast Cancer; Colorectal Cancer; Gastric Cancer; Gastrointestinal Stromal Tumors; Liver Metastases; Liver Metastasis Colon Cancer; Melanoma; Periampullary Cancer; Renal Cell Cancer; Sarcoma; Squamous Cell Carcinoma |
| NCT03714334 | DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma | Terminated | Phase 1 | 2018-10-16 | 2023-04-05 | 16 | Glioblastoma; Glioblastoma, Adult |
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 34004331 | Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme. | Seminars in cancer biology | 2022 | name in abstract: DNX-2440 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R44CA268421 | Phase 1 Study of DNX-2440 for Resectable Colorectal Liver Metastasis - IND 018569 | DNATRIX, INC. | ROBBINS, JOAN MARIE | 2022–2022 | name in title: DNX-2440 |
Notes
DNX-2440: DNX-2401 (AXP000005) backbone armed with OX40L, so a separate program under SPEC section 1. Trials in glioblastoma (NCT03714334) and, by superselective intra-arterial infusion, in liver metastases (NCT04714983).
How to cite
tezemlimogene daxadenorepvec (AXP000036.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000036.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.